Edition:
United States

Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

2.35USD
26 Sep 2016
Change (% chg)

-- (--)
Prev Close
$2.35
Open
--
Day's High
--
Day's Low
--
Volume
9,950
Avg. Vol
12,076,448
52-wk High
$9.23
52-wk Low
$1.16

Latest Key Developments (Source: Significant Developments)

Novavax Q2 loss per share $0.29
Tuesday, 9 Aug 2016 04:05pm EDT 

Novavax Inc : Novavax reports second quarter 2016 financial results . Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S . Q2 revenue fell 82 percent to $2.5 million . Q2 loss per share $0.29 . Q2 revenue view $8 million -- Thomson Reuters I/B/E/S .Says research and development expenses increased 134% to $64.9 million in q2 of 2016, compared to $27.7 million for same period in 2015.  Full Article

FDA grants fast track designation to Novavax' RSV F vaccine
Wednesday, 25 May 2016 08:00am EDT 

Novavax Inc :U.S. FDA grants fast track designation to Novavax' RSV F vaccine for older adults.  Full Article

Novavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023
Friday, 29 Jan 2016 02:54pm EST 

Novavax, Inc:Says closing of its previously announced offering of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes).Under the purchase agreement, the initial purchasers may exercise their option to purchase up to an additional $30 million aggregate principal amount of the Notes solely to cover over-allotments any time before February 24, 2016.Citigroup and J.P. Morgan acted as joint book-running managers of the offering. Piper Jaffray and Guggenheim Securities acted as Co-Lead Managers.Notes bear cash interest at a rate of 3.75%, payable on February 1 and August 1 of each year, beginning on August 1, 2016.The Notes are not redeemable prior to maturity and are convertible into shares of Novavax common stock.The initial conversion rate for the Notes is 146.8213 shares of Novavax' common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $6.81 per share of Novavax' common stock.The net proceeds of the offering were approximately $291 million, after deducting the initial purchasers' discounts and commissions, but prior to deducting estimated offering expenses.Novavax used approximately $34.7 million of the net proceeds from the offering to pay the cost of the previously announced capped call transactions.  Full Article

Novavax announces proposed offering of $200 mln of convertible senior notes due 2023
Monday, 25 Jan 2016 07:00am EST 

Novavax Inc:Announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023.Intends to use the net proceeds from the offering for the advancement of its clinical-stage vaccine candidates.  Full Article

Novavax Inc Initiates pivotal phase 3 trial of RSV F vaccine in older adults
Monday, 9 Nov 2015 06:50am EST 

Novavax Inc:Says initiation of a Phase 3 clinical trial, known as Resolve(tm), of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults.Primary efficacy objective of the Resolve trial is the prevention of moderate-severe RSV-associated lower respiratory tract disease, as defined by the presence of multiple lower respiratory tract symptoms.Top-line results expected in the second half of 2016.  Full Article

Novavax announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics
Tuesday, 29 Sep 2015 04:02pm EDT 

Novavax:Positive top-line data from a Phase 1 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in healthy children.Says All RSV F Vaccine formulations and regimens were well-tolerated and highly immunogenic.  Full Article

Novavax Inc announces positive top-line data from phase 2 clinical trial of rsv f vaccine to protect infants via maternal immunization
Tuesday, 29 Sep 2015 06:55am EDT 

Novavax Inc:Announces positive top-line data from phase 2 clinical trial of rsv f vaccine to protect infants via maternal immunization.Says efficient antibody transfer from mothers to infants observed.Says rsv f vaccine was safe and well-tolerated.Says significant anti-f, pca and microneutralizing antibody responses elicited in mothers.Says results suggest potential to protect infants when they are most at risk.  Full Article

Novavax Inc announces positive data from phase 2 trial of quadrivalent seasonal Influenza VLP
Thursday, 30 Jul 2015 08:30am EDT 

Novavax Inc:Announces positive data from phase 2 trial of quadrivalent seasonal Influenza VLP.Says trial demonstrated that seasonal influenza VLP vaccine candidate was well-tolerated.Trial demonstrated that the seasonal influenza VLP vaccine candidate showed no vaccine-related serious adverse events.Says trial met its immunogenicity targets.  Full Article

Novavax Inc announces positive top-line data from phase 1 Ebola Vaccine Trial on WHO Teleconference
Tuesday, 21 Jul 2015 08:30am EDT 

Novavax Inc:Says positive top-line data from Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M as part of World Health Organization's (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials.Trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax' proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing.  Full Article

Novavax Inc closes public offering
Tuesday, 31 Mar 2015 04:01pm EDT 

Novavax Inc:Closes underwritten public offering priced on March 25.Says it issued 27,758,620 shares of common stock, including 3,620,689 shares pursuant to the underwriters' option to purchase additional shares.Shares were issued at $7.25 per share resulting in total gross proceeds from this offering of about $201,250,000 before deducting the underwriters discount and offering expenses.Intends to use a portion of the net proceeds from this offering for the advancement of its lead vaccine candidates, including the preparation and potential initiation of Phase 3 clinical trials of its elderly RSV and maternal RSV programs and general corporate purposes.J.P. Morgan and Citigroup acted as joint book-running managers of the offering. Piper Jaffray & Co. and Wedbush PacGrow acted as Co-Lead Managers, Janney Montgomery Scott and Ladenburg Thalmann acted as Co-Managers.  Full Article

Novavax vaccine for respiratory disease fails in late stage trial

Novavax Inc said on Thursday that its experimental vaccine for a serious infectious respiratory disease failed at the final stage of human testing, sending its stock plunging more than 80 percent.